Basel Medical Group Ltd has changed its board, with Raymond Fung Keng Leong and Darren Tan leaving director roles and Yang Xinwen, Cao Juan and Frederick Hong joining. Darren Tan remains chief commercial officer, while the appointments are intended to broaden board experience and strengthen strategic Leadership and corporate governance.

Key Highlights

  • Darren Tan remains Basel Medical Group’s chief commercial officer after leaving the board.
  • None of the incoming directors hold beneficial ownership in Basel Medical Group shares.
  • Frederick Hong joins as an independent director with Capital Markets and real estate experience.

Basel Medical Group Ltd (NASDAQ: BMGL) is changing its board, with Raymond Fung Keng Leong and Darren Tan stepping down as directors with immediate effect. Yang Xinwen, Cao Juan and Frederick Hong have joined the board, while Tan continues as chief commercial officer.

New Directors Bring Commercial and Healthcare Experience

She served as Business manager at Chengdu Huiya Innovation Education Research Institute from 2023 to 2025 and is expected to contribute to commercial development, operations, internal coordination and corporate governance. Frederick Hong Shieh Ming has joined as an independent director. The appointments are also intended to reinforce strategic leadership and corporate governance capabilities. None of the new directors has beneficial ownership in Basel Medical Group shares.